

Jeevan Scientific Technology Limited

a symbol of quality and diverse solutions

Date: November 11, 2022

Ref: JSTL/BOD/BSE/2022-23/Nov22

To,
BSE Limited
1st Floor, New Trading Ring,
Rotunda Building, Phiroze Jeejeebhoy
Towers, Dalal Street, Fort,
Mumbai- 400001
(BSE Scrip Code: 538837)

Dear Sir/ Madam

Sub: Outcome of Board Meeting held on 11.11.2022

Unit: Jeevan Scientific Technology Limited (Scrip Code: 538837)

With reference to the subject cited, this is to inform the exchange that the Board Meeting of Jeevan Scientific Technology Limited held on Friday, 11-November-2022 at the registered office of the company, approved the following items of business:

- 1. Un-audited Financial Results for the quarter and half year ended 30th September 2022. (Enclosed as Annexure I).
- 2. Limited Review Report for the Quarter and half year ended 30th September 2022. (Enclosed as Annexure II).
- 3. To acquire 80% of the Shareholding by way of Investment of Rs. 2.00 Crores in Nayas Laboratories Private Limited, subject to the approval of Shareholders. Both the companies (Investing and Investee Companies) have the common promoters and the directors and hence amounts to related party transaction (Enclosed relevant disclosures as Annexure III).
- 4. Extra Ordinary General Meeting is scheduled to be held on Monday, 12.12.2022 at 10:30 a.m. through video conference or other audio visual means.

The meeting which commenced at 03:30 P.M. concluded at 6.20 P.M.

This is for your information and records.

Thanking You.

For and on Behalf of the

Jeevan Scientific Technology Limited

Krishna Kishore Kuchipudi

Vice Chairman and Managing Director

(DIN: 00876539) Encl as above

Registered Office: Plot No. 1&2, Sai Krupa Enclave, Near Lanco Hills, Golconda Post, Hyderabad- 500 008, T.S., India. Tel: +91-40-67364700 Email: info@jeevanscientific.com Web: www.jeevanscientific.com CIN: L72200TG1999PLC031016

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th SEP, 2022 Rupees in Lakhs **Ouarter Ended** Half Year Ended Year Ended **Particulars** SI.No 30-09-2022 30-06-2022 30-09-2021 30-09-2022 30-09-2021 31-03-2022 **Un Audited** Un Audited Un Audited Un Audited Un Audited Audited Income (a) Revenue From Operations 797.33 1032.79 1607.82 1830.12 5655.49 2983.86 (b) Other Income 30.7 21.46 32.68 52.16 40.62 590.98 Total income 828.03 1,054.25 1,640.50 1,882.28 3,024.48 6,246.47 Expenses (a) Cost of Material Consumed 58.45 40.92 143.41 99.37 227.10 369.43 (b) Changes in Inventories of finished goods, work-in-progress and 129.84 stock-in-trade 54.65 54.65 115.04 369.93 301.85 (c) Employee benefit expense 362.88 324.32 664.73 656.27 1502.38 (d) Finance Cost 21.81 27.19 27.74 49.00 95.83 54.49 (e) Depreciation and Amortisation expense 126.13 105.30 99.17 231.43 198.39 367.93 (f) Other Expenses 506.89 414.93 417.42 924.31 846.85 1706.07 Total Expenses 986.69 1,036,80 1,139,41 2,023,49 2.098.14 4.411.57 Profit before exceptional items and Tax (158.66)17.45 501.09 (141.21)926.34 1,834.90 Add(+)/Less(-) Exceptional items Profit / (Loss) before Tax (158.66)17.45 501.09 (141.21)926.34 1.834.90 Tax Expenses 151.68 497.93 Current Tax 282.30 Deferred Tax (39.55)(20.86)6.55 (60.41)14.12 110.66 Profit(Loss) for the period/year -119.1138.31 342.86 -80.80 629.92 1,226,31 Other Comprehensive Income (i) Items that will not be reclassfied to profit or loss (7.46)0.87 0.62 (6.59)1.25 21.03 (ii) Income tax relating to items that will not be reclassified to profit or loss B (i) Items that will be reclassified to profit or loss -(ii) Income tax relating to items that will be reclassified to profit or loss Comprehensive Income for the period /year (7.46)0.87 0.62 (6.59)1.25 21.03 9 Total Comprehensive Income for the period /year (126.57)39.18 343.48 (87.39)631.17 1,247.34 10 Paid Up Equity Share Capital (Face Value of Rs.10/- each) 1,530.15 1,530.15 1,530.15 1,530.15 1,530.15 1,530.15 Other equity excluding revaluation reserve -_ 3,548.30 2,725.91 3528.16 Earnings per Equity share (for continuing operations) a) Basic (Amount in Rupees) (0.83)0.26 2.24 (0.57)4.12 4.12 8.15

(0.83)

0.25

2.24

(0.57)

8.15

b) Diluted (Amount in Rupees)

Notes to the Un Audited Financial Results

Place: Hyderabad

Date: 11.11.2022

- 1 The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules. 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) Rules 2016.
- 2 The operations of the company has only one segment namely "Clinical "Research Services. Hence segmental reporting as per Ind AS 108 is not made.
- 3 Employee benefit expenses includes Rs. 107.53 Lakhs towards ESOP Scheme 2016 provided as per " Ind AS 102 Share Based Payments"
- 4 "The Company continues to monitor the impact of Covid-19 on its business, including its impact on customers, supply-chain, employees and logistics.
- 5 Figures for the previous periods have been rearranged/ reclassified whereever necessary to conform to the current period presentation
- The above Unaudited results have been reviewed by the Audit Committee at its meeting held on 11.11.2022 and approved by the Board of Directors of the Company on the same date.

 The results are also subjected to Limited Review by the Company's Statutory Auditors.

7 The results for the quarter ended 30th September 2022 are also available on website of BSE Limited and on the Company's website.

for Jeevan Scientific Technology Limited

HYDERABAD

K. Krishna Kishore

Vice Chairman & Managing Director

(DIN: 00876539)

Jeevan Scientific Technology Limited Un Audited Balance Sheet as at 30th Sep, 2022 (Rupees in Lakhs			
Assets	710 00 00 010 01110 1110	710 010 0 210 0 120 0 220	
(1)Non-current Assets			
a) Property, Plant and Equipment	1,683.38	1,409.62	
b) Other Intangible Assets	628.91	497.57	
c) ROU Assets	310.78	-	
d) Other non current Assets	538.77	486.51	
e) Deferred tax asset (net)	10.37	-	
(2)Current Assets			
a) Inventories	93.22	145.56	
b) Financial Assets			
i) Trade receivables	807.22	760.99	
ii) Cash and cash equivalents	54.62	134.84	
iii)Bank balances other than (ii) above	1,774.39	2,842.12	
iv)Loans & Advances (current)	249.58	58.06	
v)Other Financial Assets	322.52	777.76	
c) Current Tax Assets (Net)	227.57	624.90	
d) Other Current Assets	83.50	49.93	
Total	6,784.82	7,787.87	
Equity and Liabilities			
Equity			
a) Equity Share Capital	1,530.15	1,530.15	
b) Other Equity	3,548.30	3,528.16	
Liabilities		070.00.00	
(1)Non-current Liabilities			
a) Financial liabilities			
Borrowings	401.20	422.57	
b) Lease Liability	323.49	_	
c) Provisions	27.32	27.46	
d) Deferred tax Liability (net)	*	50.04	
(2)Current Liabilities			
a)Financial Liabilities			
i) Borrowings	325.72	831.83	
ii) Trade Payables			
Total Outstanding dues of Micro, Small and Medium			
Enterprises	59.22	34.87	
Total Outstanding dues of Creditors other than Micro, Small			
and Medium Enterprises	132.98	165.34	
iii) Other Financial liabilities	181.20	327.05	
b) Other current liabilities	248.56	374.29	
c) Provisions	6.69	496.11	
Total	6,784.82	7,787.87	

HYDERABAI

Jeevan Scientific Technolog				
Cash flow statement for the Half Year ended 30th Sep, 2022 (Rupees in Lakhs)				
Particulars	As at 30.09.2022	As at 31.03.2022		
A. Cash flow from operating activities	AS 81 30:03.2022	A5 at 31.03.2022		
Net Profit before tax and extraordinary items	(141.21)	1,834.89		
Adjustments for:	(111,21)	1,051.05		
Depreciation	231.43	367.94		
Loss on Sale of Assets	232.43	0.99		
Profit on Sale of Asset	-	(0.10)		
Interest	49.01	91.27		
Operating profit before working capital changes	139.23	2,295.00		
Changes in Working Capital		2,233.00		
Inventories	52.34	348.81		
Trade receivables	(46,23)	484.86		
Current and non current loans and advances	(191.52)	645.91		
Current and non current financial assets	455.24	(547.79)		
Other current and non current assets	311.51	(242.51)		
Trade payables	(8.00)	(63.38)		
Other financial liabilities	(145,86)	(62.91)		
Other liabilities	(125,73)	(737,30)		
Provisions	(496.16)	449.68		
Cash generated from operations before Tax	(55.18)	2,570.36		
Tax Paid	(30:20)	608.59		
Net cash from operating activity	(55.18)	1,961.77		
B. Cash flow from investing activities	(51.12)			
Purchase of fixed assets	(582,90)	(234.23)		
Repayment of Lease Liability	(40.91)	-		
Proceeds from investments	,,	102.69		
Sale/ Transfer of fixed assets		11.10		
Net cash used in investing activity	(623.82)	(120.44)		
C. Cash flow from financing activity				
Repayment of loans	(527.47)	472.34		
Interest paid	(49.01)	(91.27)		
Proposed Dividend	-	(76.51)		
Proceeds from share based paymnets	107.53	262.60		
Net cash generated in financing activity	(468.96)	567.16		
Net increase in cash and cash equivalents (A+B+C)	(1,147.95)	2,408.49		
Cash and cash equivalents at the beginning of the year/period	2,976.96	568.48		
Cash and cash equivalents at the end of the year/period	1,829.01	2,976.96		

for Jeevan Scientific Technology Limited

HYDERABAD

K. Krishna Kishore Vice Chairman & Managing Director (DIN: 00876539)

Place:Hyderabad Date:11.11.2022



PAVULURI & Co.

CHARTERED ACCOUNTANTS

Plot No.48, Flat No.301, MICASA, Phase - I, Kavuri Hills, Hyderabad - 500 033.

Ph : 040-2970 2638 / 2639 / 2640 Email : mail@pavuluriandco.com

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- 1. We have reviewed the accompanying Statement of Unaudited Financial Results of JEEVAN SCIENTIFIC TECHNOLOGY LIMITED ("the Company"), for the quarter and half year ended September 30, 2022 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PAVULURI & CO

Chartered Accountants

(Firm's Registration No. 012194S)

CA.N. RAJESH

Partner

(Membership No.223169)

UDIN: 22223169BCWGSH8230

Place: Hyderabad

Date: November 11, 2022

Annexure-III

Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015.

S.No:	Particulars	Description
1	Name of Target Entity	Nayas Laboratories Private Limited, Hyderabad
2	Related Party Transaction	 Yes. Nayas Laboratories Private Limited was promoted by Mr. K. Krishna Kishore and Mrs. K. Vanaja. The Company has two directors namely Mr. K. Krishna Kishore and Mrs. K. Vanaja. The above said two promoters are also promoters of the investing Company (Jeevan Scientific Technology Limited). Mr. K. Krishna Kishore is a Common Director on the Board of Directors of both the investing and investee companies.
3	Industry of Target entity	Pharma Sector
4	objects and effects of acquisition	Nayas Laboratories Private limited will be setting up State of Art, research and Development Lab for Formulations for Drugs which is complimentary and integrated business vertical to existing business of Jeevan Scientific Technology Limited.
5	Government and Regulatory Approvals required	Nil
6	Time period for Completion	6 months from the date of Extra Ordinary General Meeting.
7	Nature of Consideration	Cash
8	cost of acquisition or the price at which the shares are acquired;	Investment of Rs. 2.00 Crores in Nayas Laboratories Private Limited by way of subscription to the equity shares.
9	percentage of shareholding	To Acquire 80% shareholding by way of



	/ control acquired and / or number of shares acquired;	Investment of Rs. 2.00 Crores in Nayas Laboratories Private Limited. As a result, the investee Company becomes subsidiary of the investing Company on making said investment.
10	Background about the entity acquired	 Nayas Laboratories Private Limited was incorporated on 10/11/2022 with paid up capital of Rs. 5,00,000/- divided into 50,000 equity shares Rs. 10/- each. The Company was promoted by Mr. K. Krishna Kishore and Mrs. K. Vanaja. The Company has two directors namely Mr. K. Krishna Kishore and Mrs. K. Vanaja. The above said two promoters are also promoters of the investing Company (Jeevan Scientific Technology Limited). The objects of the Company (Nayas Laboratories Private Limited) include business as manufacturers, producers, buyers, sellers, importers, exporters, traders, dealers, stockiest, wholesalers and retailers, of all chemical and chemical products, Active Pharmaceutical Ingredients (bulk drugs), Drug intermediates, Formulations & semi formulation, all kind of medicines and all other related products in India and/or abroad.

